Literature DB >> 12565911

Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia.

G Van Goethem1, J J Martin, B Dermaut, A Löfgren, A Wibail, D Ververken, P Tack, I Dehaene, M Van Zandijcke, M Moonen, C Ceuterick, P De Jonghe, C Van Broeckhoven.   

Abstract

Autosomal recessive progressive external ophthalmoplegia is a mitochondrial disease characterized by accumulation of multiple large-scale deletions of mitochondrial DNA. We previously reported missense mutations in POLG, the gene encoding the mitochondrial DNA polymerase gamma in two nuclear families compatible with autosomal recessive progressive external ophthalmoplegia. Here, we report a novel POLG missense mutation (R627W) in a sporadic patient and we provide genetic support that all these POLG mutations are actually causal and recessive. The novel patient presented with sensory ataxic neuropathy and has the clinical triad of sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO). This is the first finding of a genetic cause of Sensory Ataxic Neuropathy, Dysarthria and Ophthalmoparesis and it implies that this disorder may actually be a variant of autosomal recessive progressive external ophthalmoplegia. Sensory neuropathy is the initial feature in Belgian compound heterozygote autosomal recessive progressive external ophthalmoplegia patients, all carrying the POLG A467T mutation, which occurs at a frequency of 0.6% in the Belgian population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12565911     DOI: 10.1016/s0960-8966(02)00216-x

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  59 in total

1.  Twinkle and POLG defects enhance age-dependent accumulation of mutations in the control region of mtDNA.

Authors:  Sjoerd Wanrooij; Petri Luoma; Gert van Goethem; Christine van Broeckhoven; Anu Suomalainen; Johannes N Spelbrink
Journal:  Nucleic Acids Res       Date:  2004-06-04       Impact factor: 16.971

2.  Late-onset presentation of POLG1-associated mitochondrial disease.

Authors:  Bruna Meira; Rafael Roque; Miguel Pinto; André Caetano
Journal:  BMJ Case Rep       Date:  2019-03-31

3.  Screening for POLG1 mutations in a Southern Italian ataxia population.

Authors:  C Criscuolo; P Mancini; S Ammendola; D Cicala; S Banfi; G De Michele; A Filla
Journal:  J Neurol       Date:  2007-12-19       Impact factor: 4.849

Review 4.  Inherited mitochondrial diseases of DNA replication.

Authors:  William C Copeland
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

Review 5.  Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.

Authors:  Ayman W El-Hattab; Fernando Scaglia
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 6.  Peripheral neuropathy and inborn errors of metabolism in adults.

Authors:  F Sedel; C Barnerias; O Dubourg; I Desguerres; O Lyon-Caen; Jean-Marie Saudubray
Journal:  J Inherit Metab Dis       Date:  2007-09-21       Impact factor: 4.982

Review 7.  Progressive external ophthalmoplegia characterized by multiple deletions of mitochondrial DNA: unraveling the pathogenesis of human mitochondrial DNA instability and the initiation of a genetic classification.

Authors:  Gert Van Goethem; Jean-Jacques Martin; Christine Van Broeckhoven
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

Review 8.  The mitochondrial DNA polymerase in health and disease.

Authors:  William C Copeland
Journal:  Subcell Biochem       Date:  2010

9.  Encephalomyopathies caused by abnormal nuclear-mitochondrial intergenomic cross-talk.

Authors:  C Lamperti; M Zeviani
Journal:  Acta Myol       Date:  2009-07

10.  Two families with autosomal dominant progressive external ophthalmoplegia.

Authors:  S Kiechl; R Horváth; P Luoma; U Kiechl-Kohlendorfer; B Wallacher-Scholz; R Stucka; C Thaler; J Wanschitz; A Suomalainen; M Jaksch; J Willeit
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.